Hjem › Kastringsresistent prostatakræft › New Jersey
Kastringsresistent prostatakræft kliniske forsøg i New Jersey
4 studier for Kastringsresistent prostatakræft søger deltagere på steder i New Jersey.
Officiel studietekst (engelsk)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Astera Cancer Care, East Brunswick
- Rutgers Cancer Institute of New Jersey, New Brunswick
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07225946A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- START New Jersey, East Brunswick
RekruttererFase 1
Alder 18 og opefter · Mænd · Opdateret 24. sep. 2026 · NCT07719361A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
- Novartis, East Hanover
RekruttererObservationsstudie
Alder 18 til 115 · Mænd · Opdateret 16. jul. 2026 · NCT07677267A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
- Novartis, East Hanover
RekruttererObservationsstudie
Alder 18 til 115 · Mænd · Opdateret 16. jul. 2026 · NCT07677254Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.